Home Companies Catalysts Deep Dives
Tasigna nilotinib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2007-10-29
US LOE2028-07-01
Peak Sales Est$2000M
Formulations[{"id":"tasigna-oral","doses":"50mg, 150mg, 200mg capsules","route":"Oral","setting":"PATIENT_SELF",
Companies
NVS (ORIGINATOR)100%
Mechanism: BCR-ABL inhibitor (STAMP)
Expert: Specifically targets ABL myristoyl pocket (STAMP) inhibitor of BCR-ABL1
Everyday: Blocks the abnormal protein that causes certain leukemias
Targets: ["BCR-ABL"]
Revenue History
PeriodRevenue ($M)
2024$1,680M
2025$1,550M
Programs (1)
IndicationStageKey StudyRegional Status
CMLAPPROVEDENESTnd[{"stage":"APPROVED","region":"US","approval_date":"2007-10-29"},{"stage":"APPRO
Notes
BCR-ABL inhibitor for CML. Second-gen TKI. Facing generic pressure.
Data from Supabase · Updated 2026-03-24